We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-15.07%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$113M
AUM Growth
-$24.8M
Cap. Flow
+$8.66M
Cap. Flow %
7.68%
Top 10 Hldgs %
80.31%
Holding
57
New
5
Increased
11
Reduced
3
Closed
11

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.21M
2
AMRN
Amarin Corp
AMRN
+$2.01M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$1.86M
4
BIIB icon
Biogen
BIIB
+$1.82M
5
GILD icon
Gilead Sciences
GILD
+$1.38M

Top Sells

Rank Stock Value
1
DERM
Dermira, Inc.
DERM
+$1.21M
2
WMGI
Wright Medical Group Inc
WMGI
+$914K
3
SLNO
Soleno Therapeutics
SLNO
+$877K
4
MYGN icon
Myriad Genetics
MYGN
+$817K
5
ARVN icon
Arvinas
ARVN
+$702K

Sector Composition

Rank Sector Weight
1 Healthcare 95.51%
2 Energy 0.77%
3 Consumer Staples 0.06%
4 Consumer Discretionary 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QGEN icon
51
Qiagen
QGEN
$8.47B
– –
-18,861
Closed -$676K
VCYT icon
52
Veracyte
VCYT
$4.44B
– –
-10,767
Closed -$301K
SIEN
53
DELISTED
Sientra, Inc.
SIEN
– –
-4,000
Closed -$358K
LTHM
54
DELISTED
Livent Corporation
LTHM
– –
-10,000
Closed -$86K
CLR
55
DELISTED
CONTINENTAL RESOURCES INC.
CLR
– –
-6,000
Closed -$206K
WMGI
56
DELISTED
Wright Medical Group Inc
WMGI
– –
-30,000
Closed -$914K
DERM
57
DELISTED
Dermira, Inc.
DERM
– –
-80,000
Closed -$1.21M
1 2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
USPCM
Union Square Park Capital Management New York $176M AUM 51.52% 1-Year Est. Return
FF
Farrow Financial Randolph, Vermont $176M AUM 22.38% 1-Year Est. Return

Birchview Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Birchview Capital held 57 positions worth $113M, down 18% from $138M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Birchview Capital deployed $8.66M of net new capital in Q1 2020, opening 5 new positions and adding to 11 existing holdings. Its largest new stake was Gilead Sciences: 20,000 shares worth $1.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Energy and Consumer Staples.

On the sell side, the largest reduction was Soleno Therapeutics, an estimated $877K trimmed.

  • Birchview Capital's largest Q1 2020 buy was Gilead Sciences: 20,000 shares worth $1.5M.
  • Birchview Capital added most to Acadia Pharmaceuticals in Q1 2020, an estimated $3.21M increase.
  • Birchview Capital's biggest Q1 2020 reduction was Soleno Therapeutics, cutting an estimated $877K.
  • Birchview Capital fully exited Dermira, Inc. in Q1 2020, selling an estimated $1.21M.
  • Birchview Capital's ten largest holdings make up 80% of its $113M portfolio in Q1 2020.
  • Birchview Capital opened 5 new positions and closed 11 in Q1 2020.
  • Birchview Capital's portfolio value fell 18% quarter-over-quarter to $113M.

Based on Birchview Capital's 13F filing for Q1 2020, filed 12 May 2020.